Cardlytics Inc (NASDAQ:CDLX) major shareholder Polaris Venture Management Co. sold 100,000 shares of the stock in a transaction dated Friday, June 7th. The stock was sold at an average price of $25.62, for a total transaction of $2,562,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.
Shares of CDLX stock traded down $0.46 during trading on Tuesday, hitting $25.09. The company had a trading volume of 245,800 shares, compared to its average volume of 222,782. The company has a current ratio of 2.37, a quick ratio of 2.37 and a debt-to-equity ratio of 0.99. The stock has a market cap of $574.41 million, a price-to-earnings ratio of -11.72 and a beta of 1.77. Cardlytics Inc has a 52 week low of $9.80 and a 52 week high of $28.29.
Cardlytics (NASDAQ:CDLX) last posted its quarterly earnings data on Thursday, May 9th. The company reported ($0.30) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.61) by $0.31. The company had revenue of $35.99 million for the quarter, compared to analysts’ expectations of $36.11 million. Cardlytics had a negative net margin of 25.53% and a negative return on equity of 84.02%. Cardlytics’s revenue for the quarter was up 10.0% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.35) earnings per share. As a group, sell-side analysts forecast that Cardlytics Inc will post -1.21 EPS for the current fiscal year.
A number of equities research analysts have recently issued reports on the stock. Zacks Investment Research raised shares of Cardlytics from a “hold” rating to a “buy” rating and set a $21.00 price target on the stock in a report on Wednesday, March 6th. ValuEngine cut shares of Cardlytics from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, April 23rd. SunTrust Banks restated a “buy” rating and issued a $25.00 price objective on shares of Cardlytics in a research report on Wednesday, March 6th. Finally, KeyCorp upped their price objective on shares of Cardlytics from $25.00 to $26.00 and gave the stock an “overweight” rating in a research report on Friday, May 10th. Eight investment analysts have rated the stock with a buy rating, The stock presently has an average rating of “Buy” and an average target price of $22.71.
Cardlytics, Inc operates a purchase intelligence platform in the United States and the United Kingdom. It operates in two segments, Cardlytics Direct and Other Platform Solutions. The company's platform is the Cardlytics Direct solution, a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels.
Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.